{"groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO","id":"FG000","title":"Dose Level 1 (No Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"FG001","title":"Dose Level 2 (0.025 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"FG002","title":"Dose Level 3 (0.050 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"FG003","title":"Dose Level 4 (0.10 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"FG004","title":"Dose Level 5 (0.20 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"FG005","title":"Dose Level 6 (0.40 mg/kg/Day Campath)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}